Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma
Recruiting · NCT07636252 · Observational (researchers observe without assigning treatment) · Lead sponsor: Sheba Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
Non-Interventional Study
What this trial is about
This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing.
- Patient's written informed consent present.
- Ability to understand the nature of the trial and the trial related procedures and to comply with them.
Exclusion criteria
- negative cytology for malignancy in the last 6 months
Where it is running
1 location listed.
- Sheba Medical Center - Ramat Gan, Israel, Israel